Top

Current Fungal Infection Reports

Published in:

01-03-2018 | Epidemiology of Fungal Infections (T Chiller and JW Baddley, Section Editors)

Epidemiology of Histoplasmosis

Authors: Morgan C. Scully, John W. Baddley

Published in: Current Fungal Infection Reports | Issue 1/2018

Abstract

Purpose of Review

Histoplasma capsulatum is an environmental fungus that contributes significant morbidity and mortality throughout the globe, especially in immunocompromised hosts. This review presents current data on the understanding of histoplasmosis epidemiology, including changing incidence among geographic regions and patient populations with increased risk.

Recent Findings

Global cases are more frequently identified due to the HIV epidemic, an increasing number of immunocompromised patients, and improved diagnostic capabilities. The global distribution of histoplasmosis extends to several countries in Central and South America and the Caribbean, as well as southern and sub-Saharan Africa, India, China, and Southeast Asia. Cases are also seen throughout Europe and non-endemic regions of the USA often due to migration and travelers.

Summary

The changing epidemiology of histoplasmosis underlines the importance of continued surveillance and reporting to better understand the regions which place patients at a higher risk for infection.

•• Bahr NC, Antinori S, Wheat LJ, Sarosi GA. Histoplasmosis infections worldwide: thinking outside of the Ohio River valley. Curr Trop Med Rep. 2015;1:70–80. Provides comprehensive mapping of reported cases of histoplasmosis and skin testing results worldwide. CrossRef

Benedict K, Mody RK. Epidemiology of histoplasmosis outbreaks, United States, 1938–2013. Emerg Infect Dis. 2016;22(3):370–8. https://doi.org/10.3201/eid2203.151117.CrossRefPubMedPubMedCentral

Edwards LB, Acquaviva FA, Livesay VT, Cross FW, Palmer CE. An atlas of sensitivity to tuberculin, PPD-B, and histoplasmin in the United States. Am Rev Respir Dis. 1969;99(Suppl):1–132.

Wheat LJ. Histoplasmosis: a review for clinicians from non-endemic areas. Mycoses. 2006;49(4):274–82. https://doi.org/10.1111/j.1439-0507.2006.01253.x.CrossRefPubMed

Gopalakrishnan R, Nambi PS, Ramasubramanian V, Abdul Ghafur K, Parameswaran A. Histoplasmosis in India: truly uncommon or uncommonly recognized? J Assoc Physicians India. 2012;60:25–8.PubMed

Subramanian S, Abraham OC, Rupali P, Zachariah A, Mathews MS, Mathai D. Disseminated histoplasmosis. J Assoc Physicians India. 2005;53:185–9.PubMed

•• Pan B, Chen M, Pan W, Liao W. Histplasmosis: a new endemic fungal infection in China? Review and analysis of cases. Mycoses. 2012;56:212–21. Important recognition of new areas of histoplasmosis endemicity. CrossRefPubMed

Gugnani HC. Histoplasmosis in Africa: a review. Indian J Chest Dis Allied Sci. 2000;42(4):271–7.PubMed

Ashbee HR, Evans EGV, Viviani MA, et al. Histoplasmosis in Europe: report on an epidemiological survey from the European Confederation of Medical Mycology Working Group. Med Mycol. 2008;46(1):57–65. https://doi.org/10.1080/13693780701591481.CrossRefPubMed

10.

Chastain DB, Henao-Martinez AF, Franco-Paredes C. Opportunistic invasive mycoses in AIDS: cryptococcosis, histoplasmosis, coccidiodomycosis, and talaromycosis. Curr Infect Dis Rep. 2017;19(10):36. https://doi.org/10.1007/s11908-017-0592-7.CrossRefPubMed

11.

Kauffman CA. Histoplasmosis: a clinical and laboratory update. Clin Microbiol Rev. 2007;20(1):115–32. https://doi.org/10.1128/CMR.00027-06.CrossRefPubMedPubMedCentral

12.

Azar MM, Hage CA. Laboratory diagnostics for histoplasmosis. J Clin Microbiol. 2017;55(6):1612–20. https://doi.org/10.1128/JCM.02430-16.CrossRefPubMedPubMedCentral

13.

Colombo AL, Tobon A, Restrepo A, et al. Epidemiology of endemic systemic fungal infections in Latin America. Med Mycol. 2011;49(8):785–98. https://doi.org/10.3109/13693786.2011.577821.PubMed

14.

Karimi K, Wheat LJ, Connolly P, Cloud G, Hajjeh R, Wheat E, et al. Differences in histoplasmosis in patients with acquired immunodeficiency syndrome in the United States and Brazil. J Infect Dis. 2002;186(11):1655–60. https://doi.org/10.1086/345724.CrossRefPubMed

15.

• Arango M, Castañeda E, Agudelo CI, De Bedout C, Agudelo CA, Tobón A, et al. Histoplasmosis: results of the Colombian national survey, 1992–2008. Biomed Rev Inst Nac Salud. 2011;31:344–56. Summary of Colombian histoplasmosis patients showing a large percentage of HIV/AIDs patient and low percentage of antifungal treatment.

16.

Taylor ML, Pérez-Mejía A, Yamamoto-Furusho JK, Granados J. Immunologic, genetic and social human risk factors associated to histoplasmosis: studies in the State of Guerrero, Mexico. Mycopathologia. 1997;138(3):137–42. https://doi.org/10.1023/A:1006847630347.CrossRefPubMed

17.

Mata-Essayag S, Colella MT, Roselló A, de Capriles CH, Landaeta ME, de Salazar CP, et al. Histoplasmosis: a study of 158 cases in Venezuela, 2000–2005. Medicine (Baltimore). 2008;87(4):193–202. https://doi.org/10.1097/MD.0b013e31817fa2a8.CrossRef

18.

Hay RJ, White HS, Fields PE, Quamina DB, Dan M, Jones TR. Histoplasmosis in the eastern Caribbean: a preliminary survey of the incidence of the infection. J Trop Med Hyg. 1981;84(1):9–12.PubMed

19.

Denning DW, Gugnani HC. Burden of serious fungal infections in Trinidad and Tobago. Mycoses. 2015;58(Suppl 5):80–4. https://doi.org/10.1111/myc.12394.CrossRefPubMed

20.

Bezjak V, Farsey SJ. Prevalence of skin sensitivity to histoplasmin and coccidioidin in varous Ugandan populations. Am J Trop Med Hyg. 1970;19(4):664–9. https://doi.org/10.4269/ajtmh.1970.19.664.CrossRefPubMed

21.

Gugnani HC, Denning DW, Rahim R, Sadat A, Belal M, Mahbub MS. Burden of serious fungal infections in Bangladesh. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 2017;36(6):993–7. https://doi.org/10.1007/s10096-017-2921-z.CrossRef

22.

Matin N, Shahrin L, Pervez MM, Banu S, Ahmed D, Khatun M, et al. Clinical profile of HIV/AIDS-infected patients admitted to a new specialist unit in Dhaka, Bangladesh—a low-prevalence country for HIV. J Health Popul Nutr. 2011;29(1):14–9.CrossRefPubMedPubMedCentral

23.

Chakrabarti A, Slavin MA. Endemic fungal infections in the Asia-Pacific region. Med Mycol. 2011;49(4):337–44. https://doi.org/10.3109/13693786.2010.551426.CrossRefPubMed

24.

Manos NE, Ferebee SH, Kerschbaum WF. Geographic variation in the prevalence of histoplasmin sensitivity. Dis Chest. 1956;29(6):649–68. https://doi.org/10.1378/chest.29.6.649.CrossRefPubMed

25.

Baddley JW, Winthrop KL, Patkar NM, Delzell E, Beukelman T, Xie F, et al. Geographic distribution of endemic fungal infections among older persons, United States. Emerg Infect Dis. 2011;17(9):1664–9. https://doi.org/10.3201/eid1709.101987.CrossRefPubMedPubMedCentral

26.

Weinberg M, Weeks J, Lance-Parker S, Traeger M, Wiersma S, Phan Q, et al. Severe histoplasmosis in travelers to Nicaragua. Emerg Infect Dis. 2003;9(10):1322–5. https://doi.org/10.3201/eid0910.030049.CrossRefPubMedPubMedCentral

27.

Gutierrez ME, Canton A, Sosa N, Puga E, Talavera L. Disseminated histoplasmosis in patients with AIDS in Panama: a review of 104 cases. Clin Infect Dis. 2005;40(8):1199–202. https://doi.org/10.1086/428842.CrossRefPubMed

28.

Chang MR, Taira CL, Paniago AMM, Taira DL, Cunha RV, Wanke B. Study of 30 cases of histoplasmosis observed in Mato Grosso Do Sul state, Brazil. J Sao Paulo Inst Trop Med. 2007;49(1):37–9. https://doi.org/10.1590/S0036-46652007000100007.CrossRef

29.

Giacomazzi J, Baethgen L, Carneiro LC, et al. The burden of serious human fungal infections in Brazil. Mycoses. 2015;59:145–50.CrossRefPubMed

30.

Guimaraes LFA, Halpern M, de Lemos AS, et al. Invasive fungal disease in renal transplant recipients at a Brazilian center: local epidemiology matters. Transplant Proc. 2016;48(7):2306–9. https://doi.org/10.1016/j.transproceed.2016.06.019.CrossRefPubMed

31.

Martínez Méndez D, Hernández Valles R, Alvarado P, Mendoza M. Mycoses in Venezuela: Working Groups in Mycology reported cases (1984–2010). Rev Iberoam Micol. 2013;30(1):39–46. https://doi.org/10.1016/j.riam.2012.10.001.CrossRefPubMed

32.

Cermeño JR, Cermeño JJ, Hernández I, Godoy G, Cermeño JJ, Cabello I, et al. Histoplasmine and paracoccidiodine epidemiological study in Upata, Bolívar state, Venezuela. Trop Med Int Health TM IH. 2005;10(3):216–9. https://doi.org/10.1111/j.1365-3156.2004.01376.x.CrossRefPubMed

33.

Caceres DH, Zuluaga A, Arango-Bustamante K, de Bedout C, Tobón ÁM, Restrepo Á, et al. Implementation of a training course increased the diagnosis of histoplasmosis in Colombia. Am J Trop Med Hyg. 2015;93(3):662–7. https://doi.org/10.4269/ajtmh.15-0108.CrossRefPubMedPubMedCentral

34.

Nieto-Ríos JF, Serna-Higuita LM, Guzman-Luna CE, Ocampo-Kohn C, Aristizabal-Alzate A, Ramírez I, et al. Histoplasmosis in renal transplant patients in an endemic area at a reference hospital in Medellin, Colombia. Transplant Proc. 2014;46(9):3004–9. https://doi.org/10.1016/j.transproceed.2014.06.060.CrossRefPubMed

35.

Nacher M, Adenis A, Mc Donald S, Do Socorro Mendonca Gomes M, Singh S, Lopes Lima I, et al. Disseminated histoplasmosis in HIV-infected patients in South America: a neglected killer continues on its rampage. PLoS Negl Trop Dis. 2013;7(11):e2319. https://doi.org/10.1371/journal.pntd.0002319.CrossRefPubMedPubMedCentral

36.

The neglected histoplasmosis in Latin America Group. Disseminated histoplasmosis in Central and South America, the invisible elephant: the lethal blind spot of international health organizations. AIDS Lond Engl. 2016;30:167–70.CrossRef

37.

Nacher M, Adenis A, Aznar C, Blanchet D, Vantilcke V, Demar M, et al. How many have died from undiagnosed human immunodeficiency virus-associated histoplasmosis, a treatable disease? Time to act. Am J Trop Med Hyg. 2014;90(2):193–4. https://doi.org/10.4269/ajtmh.13-0226.CrossRefPubMedPubMedCentral

38.

•• Medina N, Samayoa B, Lau-Bonilla D, Denning DW, Herrera R, Mercado D, et al. Burden of serious fungal infections in Guatemala. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 2017;36(6):965–9. Evidence from Central America that prediction of cases much higher than reported raising concerns for missed diagnosis. https://doi.org/10.1007/s10096-017-2920-0.CrossRef

39.

Nacher M, Aznar C, Blanchet D, Demar M, El Guedj M, Vaz T, et al. AIDS-related disseminated histoplasmosis in the greater Caribbean: how frequent is it? AIDS Lond Engl. 2006;20(6):951–2. https://doi.org/10.1097/01.aids.0000218568.43391.78.CrossRef

40.

Lewden C, Sobesky M, Cabié A, Couppié P, Boulard F, Bissuel F, et al. Causes of death among HIV infected adults in French Guyana and the French West Indies in the era of highly active antiretroviral therapy (HAART). Med Mal Infect. 2004;34(7):286–92. https://doi.org/10.1016/S0399-077X(04)00146-5.CrossRefPubMed

41.

Huber F, Nacher M, Aznar C, Pierre-Demar M, El Guedj M, Vaz T, et al. AIDS-related Histoplasma capsulatum var. capsulatum infection: 25 years experience of French Guiana. AIDS Lond Engl. 2008;22(9):1047–53. https://doi.org/10.1097/QAD.0b013e3282ffde67.CrossRef

42.

Gugnani HC, Denning DW. Burden of serious fungal infections in the Dominican Republic. J Infect Public Health. 2016;9(1):7–12. https://doi.org/10.1016/j.jiph.2015.04.026.CrossRefPubMed

43.

Centers for Disease Control and Prevention (CDC). Outbreak of histoplasmosis among travelers returning from El Salvador—Pennsylvania and Virginia, 2008. MMWR Morb Mortal Wkly Rep. 2008;57:1349–53.

44.

Morgan J, Cano MV, Feikin DR, Phelan M, Monroy OV, Morales PK, et al. A large outbreak of histoplasmosis among American travelers associated with a hotel in Acapulco, Mexico, spring 2001. Am J Trop Med Hyg. 2003;69(6):663–9.PubMed

45.

Gascón J, Torres JM, Jiménez M, Mejias T, Triviño L, Gobbi F, et al. Histoplasmosis infection in Spanish travelers to Latin America. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 2005;24(12):839–41. https://doi.org/10.1007/s10096-005-0050-6.CrossRef

46.

Bahr NC, Sarosi GA, Meya DB, Bohjanen PR, Richer SM, Swartzentruber S, et al. Seroprevalence of histoplasmosis in Kampala, Uganda. Med Mycol. 2016;54(3):295–300. https://doi.org/10.1093/mmy/myv081.CrossRefPubMed

47.

Mandengue CE, Ngandjio A, Atangana PJA. Histoplasmosis in HIV-infected persons, Yaoundé, Cameroon. Emerg Infect Dis. 2015;21(11):2094–6. https://doi.org/10.3201/eid2111.150278.CrossRefPubMedPubMedCentral

48.

Inojosa W, Rossi MC, Laurino L, Giobbia M, Fuser R, Carniato A, et al. Progressive disseminated histoplasmosis among human immunodeficiency virus-infected patients from West-Africa: report of four imported cases in Italy. Infez Med Riv Period Eziologia Epidemiol Diagn Clin E Ter Delle Patol Infett. 2011;19:49–55.

49.

Lai C-H, Huang C-K, Chin C, Yang Y-T, Lin H-F, Lin H-H. Indigenous case of disseminated histoplasmosis, Taiwan. Emerg Infect Dis. 2007;13(1):127–9. https://doi.org/10.3201/eid1301.060857.CrossRefPubMedPubMedCentral

50.

Kikuchi K, Sugita T, Makimura K, Urata K, Someya T, Sasaki T, et al. Is Histoplasma capsulatum a native inhabitant of Japan? Microbiol Immunol. 2008;52(9):455–9. https://doi.org/10.1111/j.1348-0421.2008.00052.x.CrossRefPubMed

51.

Ohno H, Ogata Y, Suguro H, Yokota S, Watanabe A, Kamei K, et al. An outbreak of histoplasmosis among healthy young Japanese women after traveling to Southeast Asia. Intern Med Tokyo Jpn. 2010;49(5):491–5. https://doi.org/10.2169/internalmedicine.49.2759.CrossRef

52.

Wang TL, Cheah JS, Holmberg K. Case report and review of disseminated histoplasmosis in South-East Asia: clinical and epidemiological implications. Trop Med Int Health TM IH. 1996;1(1):35–42. https://doi.org/10.1046/j.1365-3156.1996.d01-10.x.CrossRefPubMed

53.

Bun Navy K, Prem Prey S, Lynen L, Sovanna P, Bell JD, Harwell JI. The first reported cases of disseminated histoplasmosis in Cambodia, complicated by multiple opportunistic infections. Southeast Asian J Trop Med Public Health. 2005;36(5):1272–4.PubMed

54.

Norkaew T, Ohno H, Sriburee P, Tanabe K, Tharavichitkul P, Takarn P, et al. Detection of environmental sources of Histoplasma capsulatum in Chiang Mai, Thailand, by nested PCR. Mycopathologia. 2013;176(5-6):395–402. https://doi.org/10.1007/s11046-013-9701-9.CrossRefPubMed

55.

McLeod DSA, Mortimer RH, Perry-Keene DA, Allworth A, Woods ML, Perry-Keene J, et al. Histoplasmosis in Australia: report of 16 cases and literature review. Medicine (Baltimore). 2011;90(1):61–8. https://doi.org/10.1097/MD.0b013e318206e499.CrossRef

56.

• Martin-Iguacel R, Kurtzhals J, Jouvion G, Nielsen SD, Llibre JM. Progressive disseminated histoplasmosis in the HIV population in Europe in the HAART era. Case report and literature review. Infection. 2014;42(4):611–20. Highlights cases in Europe largely acquired from Africa and Central/South America. Importance of understanding the disease even in a non-endemic area. https://doi.org/10.1007/s15010-014-0611-7.CrossRefPubMed

57.

Buitrago MJ, Bernal-Martínez L, Castelli MV, Rodríguez-Tudela JL, Cuenca-Estrella M. Histoplasmosis and paracoccidioidomycosis in a non-endemic area: a review of cases and diagnosis. J Travel Med. 2011;18(1):26–33. https://doi.org/10.1111/j.1708-8305.2010.00477.x.CrossRefPubMed

58.

Anderson AM, Mehta AK, Wang YF, Qian J, Easley K, Nguyen MLT. HIV-associated histoplasmosis in a nonendemic area of the United States during the HAART era: role of migration from endemic areas and lack of antiretroviral therapy. J Int Assoc Phys AIDS Care Chic Ill. 2010;9:296–300.CrossRef

59.

•• Benedict K, Thompson GR, Deresinski S, Chiller T. Mycotic infections acquired outside areas of known endemicity, United States. Emerg Infect Dis. 2015;21(11):1935–41. Demonstrates the presentation and environmental exposures seen in non-endemic cases in the USA. https://doi.org/10.3201/eid2111.141950.CrossRefPubMedPubMedCentral

60.

Chu JH, Feudtner C, Heydon K, Walsh TJ, Zaoutis TE. Hospitalizations for endemic mycoses: a population-based national study. Clin Infect Dis Off Publ Infect Dis Soc Am. 2006;42(6):822–5. https://doi.org/10.1086/500405.CrossRef

61.

Ordonez ME, Farraye FA, Di Palma JA. Endemic fungal infections in inflammatory bowel disease associated with anti-TNF antibody therapy. Inflamm Bowel Dis. 2013;19(11):2490–500. https://doi.org/10.1097/MIB.0b013e31828f1fba.CrossRefPubMed

62.

Olson TC, Bongartz T, Crowson CS, Roberts GD, Orenstein R, Matteson EL. Histoplasmosis infection in patients with rheumatoid arthritis, 1998–2009. BMC Infect Dis. 2011;11(1):145. https://doi.org/10.1186/1471-2334-11-145.CrossRefPubMedPubMedCentral

63.

Winthrop KL, Yamashita S, Beekmann SE, Polgreen PM, Infectious Diseases Society of America Emerging Infections Network. Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network. Clin Infect Dis Off Publ Infect Dis Soc Am. 2008;46(11):1738–40. https://doi.org/10.1086/587989.CrossRef

64.

Wallis RS, Broder M, Wong J, Lee A, Hoq L. Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis Off Publ Infect Dis Soc Am. 2005;41(Suppl 3):S194–8.CrossRef

65.

Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc. 2008;83(2):181–94. https://doi.org/10.1016/S0025-6196(11)60839-2.CrossRefPubMed

66.

Hage CA, Bowyer S, Tarvin SE, Helper D, Kleiman MB, Wheat LJ. Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy. Clin Infect Dis Off Publ Infect Dis Soc Am. 2010;50(1):85–92. https://doi.org/10.1086/648724.CrossRef

67.

• Vergidis P, Avery RK, Wheat LJ, Dotson JL, Assi MA, Antoun SA, et al. Histoplasmosis complicating tumor necrosis factor-α blocker therapy: a retrospective analysis of 98 cases. Clin Infect Dis Off Publ Infect Dis Soc Am. 2015;61(3):409–17. Review of risks with TNF blockers including steroid use. Resumption of TNF inhibitor appeared safe as long as antifungal prophylaxis continued. https://doi.org/10.1093/cid/civ299.CrossRef

68.

Wheat LJ, Freifeld AG, Kleiman MB, Baddley JW, McKinsey DS, Loyd JE, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis Off Publ Infect Dis Soc Am. 2007;45(7):807–25. https://doi.org/10.1086/521259.CrossRef

69.

Smith JA, Kauffman CA. Endemic fungal infections in patients receiving tumour necrosis factor-alpha inhibitor therapy. Drugs. 2009;69(11):1403–15. https://doi.org/10.2165/00003495-200969110-00002.CrossRefPubMed

70.

Vail GM, Young RS, Wheat LJ, Filo RS, Cornetta K, Goldman M. Incidence of histoplasmosis following allogeneic bone marrow transplant or solid organ transplant in a hyperendemic area. Transpl Infect Dis Off J Transplant Soc. 2002;4(3):148–51. https://doi.org/10.1034/j.1399-3062.2002.01016.x.CrossRef

71.

Grim SA, Proia L, Miller R, Alhyraba M, Costas-Chavarri A, Oberholzer J, et al. A multicenter study of histoplasmosis and blastomycosis after solid organ transplantation. Transpl Infect Dis Off J Transplant Soc. 2012;14(1):17–23. https://doi.org/10.1111/j.1399-3062.2011.00658.x.CrossRef

Title: Epidemiology of Histoplasmosis
Authors: Morgan C. Scully
John W. Baddley
Publication date: 01-03-2018
Publisher: Springer US
Published in: Current Fungal Infection Reports / Issue 1/2018
Print ISSN: 1936-3761
Electronic ISSN: 1936-377X
DOI: https://doi.org/10.1007/s12281-018-0309-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 1/2018

Pathogenesis and Pathology of Invasive Aspergillosis

A Case for Antifungal Stewardship

Emergomyces: a New Genus of Dimorphic Fungal Pathogens Causing Disseminated Disease among Immunocompromised Persons Globally

Challenges in the Diagnosis of Invasive Fungal Infections in Immunocompromised Hosts

Antifungal Dosing Considerations in Patients Undergoing Continuous Renal Replacement Therapy

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage